<DOC>
	<DOCNO>NCT01632527</DOCNO>
	<brief_summary>The purpose Phase I/II study investigate safety preliminary efficacy unilateral subretinal transplantation HuCNS-SC cell subject geographic atrophy secondary age-related macular degeneration .</brief_summary>
	<brief_title>Study Human Central Nervous System Stem Cells ( HuCNS-SC ) Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>This study open-label dose-escalation investigation safety preliminary efficacy unilateral subretinal transplantation HuCNS-SC cell subject Geographic Atrophy secondary Age-Related Macular Degeneration ( AMD ) . Subjects enrol base specific inclusion/exclusion criterion evaluate regular post transplant interval . The investigation divide two sequential cohort . Subjects enrol cohort base best-corrected visual acuity ( BCVA ) visual acuity determine Electronic Early Treatment Diabetic Retinopathy Study ( E-ETDRS ) acuity test . BCVA le equal 20/400 Study Eye enrol Cohort I . Subjects BCVA 20/320 20/100 Study Eye enrol Cohort II . Cohort I consist four subject undergo transplant 200,000 cell follow four subject undergo transplant 1 million cell . Cohort II consist 7 subject undergo transplant 1 million cell . An independent Data Monitoring Committee ( DMC ) review accrue safety data subject . HuCNS-SC cell transplant board-certified vitreoretinal surgeon . The transplantation conduct eye inferior best-corrected visual acuity ( BCVA ) ( i.e. , Study Eye ) . Only Study Eye undergo transplantation . The HuCNS-SC cell administer subretinal space standard surgical approach . Immunosuppressive agent administer orally subject period three month surgery . Subjects monitor frequently total one year HuCNS-SC cell transplantation . An additional four year monitor conducted separate follow-up study commence termination visit Phase I/II investigation . The follow-up study conduct separate investigation .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Diagnosis agerelated macular degeneration geographic atrophy ( GA ) Only patient specific degree extent GA eligible Subjects bestcorrected visual acuity ( BCVA ) less equal 20/400 Study Eye enrol Cohort I . Subjects BCVA 20/320 20/100 Study Eye enrol Cohort II No prior current choroidal neovascularization either eye Must adequate caregiver support access medical care local community Able provide write informed consent prior study related procedure Agree comply good faith condition study attend require study visit Prior vitreal retinal surgery Glaucoma Atrophic macular disease cause Diabetic retinopathy diabetic macular edema either eye Previous organ , tissue bone marrow transplantation Previous participation gene transfer cell transplant trial Autoimmune disease Allergy tacrolimus , mycophenolate mofetil ( MMF ) , scopolamine , Cyclogyl , Moxifloxacin , Gatifloxacin Current prior malignancy ( chemotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Dry AMD GA</keyword>
	<keyword>Geographic Atrophy Age-Related Macular Degeneration</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Stem Cell transplant</keyword>
	<keyword>Stem cell AMD</keyword>
	<keyword>Human neural stem cell</keyword>
	<keyword>multipotent stem cell</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Dry AMD</keyword>
	<keyword>Human central nervous system stemcells</keyword>
	<keyword>dry age-related macular degeneration</keyword>
</DOC>